These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17925336)

  • 1. Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia.
    Mari A; Scherbaum WA; Nilsson PM; Lalanne G; Schweizer A; Dunning BE; Jauffret S; Foley JE
    J Clin Endocrinol Metab; 2008 Jan; 93(1):103-9. PubMed ID: 17925336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial.
    Foley JE; Bunck MC; Möller-Goede DL; Poelma M; Nijpels G; Eekhoff EM; Schweizer A; Heine RJ; Diamant M
    Diabetologia; 2011 Aug; 54(8):1985-91. PubMed ID: 21547496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia.
    Scherbaum WA; Schweizer A; Mari A; Nilsson PM; Lalanne G; Wang Y; Dunning BE; Foley JE
    Diabetes Obes Metab; 2008 Nov; 10(11):1114-24. PubMed ID: 18355325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
    Ahrén B; Schweizer A; Dejager S; Dunning BE; Nilsson PM; Persson M; Foley JE
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1236-43. PubMed ID: 19174497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.
    Scherbaum WA; Schweizer A; Mari A; Nilsson PM; Lalanne G; Jauffret S; Foley JE
    Diabetes Obes Metab; 2008 Aug; 10(8):675-82. PubMed ID: 18248490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database.
    Pratley RE; Schweizer A; Rosenstock J; Foley JE; Banerji MA; Pi-Sunyer FX; Mills D; Dejager S
    Diabetes Obes Metab; 2008 Sep; 10(10):931-8. PubMed ID: 18093207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DPP-4 inhibitor treatment: β-cell response but not HbA
    Kozlovski P; Bhosekar V; Foley JE
    Vasc Health Risk Manag; 2017; 13():123-126. PubMed ID: 28408838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.
    González-Ortiz M; Sánchez-Peña MJ; González-Ortiz LJ; Robles-Cervantes JA; García-Ortega YE; Gómez-Gaitán EA; Pérez-Rubio KG; Martínez-Abundis E
    Diabetes Technol Ther; 2013 Jul; 15(7):564-8. PubMed ID: 23617250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
    Garber AJ; Schweizer A; Baron MA; Rochotte E; Dejager S
    Diabetes Obes Metab; 2007 Mar; 9(2):166-74. PubMed ID: 17300592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
    Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    Diabetes Obes Metab; 2014 Sep; 16(9):812-8. PubMed ID: 24612221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
    Kalra S
    J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
    D'Alessio DA; Denney AM; Hermiller LM; Prigeon RL; Martin JM; Tharp WG; Saylan ML; He Y; Dunning BE; Foley JE; Pratley RE
    J Clin Endocrinol Metab; 2009 Jan; 94(1):81-8. PubMed ID: 18957505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.
    Utzschneider KM; Tong J; Montgomery B; Udayasankar J; Gerchman F; Marcovina SM; Watson CE; Ligueros-Saylan MA; Foley JE; Holst JJ; Deacon CF; Kahn SE
    Diabetes Care; 2008 Jan; 31(1):108-13. PubMed ID: 17909087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
    Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
    Lukashevich V; Schweizer A; Foley JE; Dickinson S; Groop PH; Kothny W
    Vasc Health Risk Manag; 2013; 9():21-8. PubMed ID: 23378769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3799-806. PubMed ID: 22855332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
    Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
    Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.
    Dejager S; Razac S; Foley JE; Schweizer A
    Horm Metab Res; 2007 Mar; 39(3):218-23. PubMed ID: 17373638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus.
    Zografou I; Sampanis C; Gkaliagkousi E; Iliadis F; Papageorgiou A; Doukelis P; Vogiatzis K; Douma S
    Hormones (Athens); 2015; 14(1):118-25. PubMed ID: 25402372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.